Australia markets closed

Exopharm Limited (EX1.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0910+0.0010 (+1.11%)
At close: 04:10PM AEDT

Exopharm Limited

31 Queen Street
Level 17
Melbourne, VIC 3000
Australia
61 3 9111 0026
https://www.exopharm.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees50

Key executives

NameTitlePayExercisedYear born
Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.Founder, Technology Co-Founder, CEO MD & Director429.16kN/AN/A
Dr. Michael L. West Ph.D.Chief Technology Officer196.46kN/A1964
Mr. David OxleyPres of International344.4kN/AN/A
Dr. Gregor Lichtfuss M.Sc.Co-Founder & Bus. Services Mang.N/AN/AN/A
Mr. Johannes MuhlSr. VP of Fin.N/AN/AN/A
Caitlin GladmanVP of CommunicationsN/AN/AN/A
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP.Company Sec.N/AN/A1970
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Exopharm Limited, a clinical-stage company, develops transformative medicines based upon extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to guide them to target tissues or cell types; leveraging oligonucleotide packing for amplified dosing, which enables specific RNA molecules to be preferentially loaded into exosomes as a therapeutic cargo; ligand-based exosome affinity purification that isolates and purifies exosomes from biofluids like blood and cell culture media. Its engineered EVs products comprise Fortrexo CoV for the treatment of SARS-CoV-2 infection; Cognevo for the treatment of neuro degeneration; and PlexoDox for the treatment of cancer. Exopharm Limited has a research collaboration with Showa Denko Materials Co., Ltd. The company was incorporated in 2013 and is based in Melbourne, Australia.

Corporate governance

Exopharm Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.